This compound has beenstudied for its potential application in the theranostics of breastcancer.145,146 A 2018 study confirmed the potential applicationof [64Cu]-DOTA-trastuzumab PET-CT in modifying therapyfor HER2+ patients with metastatic breast cancer: the findings indicatea direct relationship between the absorption of [64Cu]-DOTA-trastuzumabby the tumor and the HER2 status. The gene discussed is ERBB2; the disease is neoplasm.